Experience with Tafamidis in peritoneal dialysis for a patient diagnosed with transthyretin cardiac amyloidosis

Abstract

Cardiac amyloidosis is a cardiomyopathy resulting from the extracellular deposition of proteins such as transthyretin (TTR). We present the case of a 72-year-old male with hereditary cardiac amyloidosis (ATTRh). After confirming the diagnosis, Tafamidis, a TTR stabilizer, was administered. Remarkably, Tafamidis, when coupled with peritoneal dialysis for chronic kidney disease, maintained stability in both cardiac and renal functions. Previous studies have demonstrated Tafamidis’ efficacy in reducing all-cause mortality and cardiovascular hospitalizations, although its use in severe renal failure lacks specific evaluation. This case suggests a potential application of Tafamidis in moderate-severe kidney disease, emphasizing the need for further research in this population.